JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

JNJ

170.71

-0.01%↓

ABBV

196.37

-1.09%↓

AZN

73.59

-1.13%↓

NVS

113.55

-3.58%↓

ABT

130.95

+0.14%↑

Search

MannKind Corp

Cerrado

SectorSalud

3.47 -13.03

Resumen

Variación precio

24h

Actual

Mínimo

3.45

Máximo

3.99

Métricas clave

By Trading Economics

Ingresos

5.7M

13M

Ventas

1.6M

78M

P/B

Media del Sector

39.2

34.393

Margen de beneficio

16.793

Empleados

403

EBITDA

8.3M

27M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+120.55% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-316M

1.2B

Apertura anterior

16.5

Cierre anterior

3.47

Noticias sobre sentimiento de mercado

By Acuity

74%

26%

348 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

MannKind Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 ago 2025, 22:24 UTC

Ganancias
Principales Movimientos del Mercado

Airbnb Logs 2Q Beat, But Investments Weigh on Margin Outlook -- Update

6 ago 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Earnings, U.S. Tariffs -- Market Talk

6 ago 2025, 23:39 UTC

Charlas de Mercado

Gold Steady as Traders Assess Geopolitical, Tariff Developments -- Market Talk

6 ago 2025, 23:28 UTC

Ganancias

Kakao 2Q Net Profit Beat FactSet-Compiled Consensus

6 ago 2025, 23:28 UTC

Ganancias

Kakao 2Q Net KRW171.82B Vs. Net KRW87.15B >035720.SE

6 ago 2025, 23:28 UTC

Ganancias

Kakao 2Q Oper Pft KRW185.93B Vs. Pft KRW133.96B >035720.SE

6 ago 2025, 23:28 UTC

Ganancias

Kakao 2Q Rev KRW2.028T Vs. KRW2.005T >035720.SE

6 ago 2025, 23:14 UTC

Ganancias

Fiserv, Shift4, Toast Stocks Tumble on Earnings. Analysts Are Optimistic Anyway. -- Barrons.com

6 ago 2025, 23:01 UTC

Ganancias

United Overseas Bank 2Q Net Interest Income S$2.34B Vs. S$2.40B >U11.SG

6 ago 2025, 23:01 UTC

Ganancias

United Overseas Bank 2Q Total Income S$3.47B Vs. S$3.48B >U11.SG

6 ago 2025, 23:00 UTC

Ganancias

United Overseas Bank 2Q Net S$1.34B Vs. Net S$1.43B >U11.SG

6 ago 2025, 22:54 UTC

Charlas de Mercado

New Zealand Companies Should Avoid Qualifying Profit Improvement -- Market Talk

6 ago 2025, 22:41 UTC

Ganancias

DBS 2Q Allowances for Credit, Other Losses S$133.0M Vs. S$148.0M >D05.SG

6 ago 2025, 22:38 UTC

Ganancias

DBS 2Q Net Interest Income S$3.63B Vs. S$3.77B >D05.SG

6 ago 2025, 22:38 UTC

Ganancias

DBS 2Q Total Income S$5.73B Vs. S$5.48B >D05.SG

6 ago 2025, 22:38 UTC

Ganancias

DBS 2Q Net S$2.82B Vs. Net S$2.80B >D05.SG

6 ago 2025, 22:28 UTC

Charlas de Mercado

NZX Bear Says Growth Likely to Miss Market's Hopes -- Market Talk

6 ago 2025, 22:11 UTC

Ganancias

Pan American Silver 2Q Rev $811.90 >PAAS

6 ago 2025, 22:11 UTC

Ganancias

Pan American Silver Raises Dividend to 12c >PAAS

6 ago 2025, 22:11 UTC

Ganancias

Pan American Silver 2Q EPS 52c >PAAS

6 ago 2025, 22:03 UTC

Ganancias

Nutrien 2Q Sales $10.44B >NTR.T

6 ago 2025, 22:03 UTC

Ganancias

Nutrien: Nitrogen Sales Volume Guidance of 10.7MMT to 11.2MMT Assumes Lower Ammonia Operating Rates in 2H Compared to Record Achieved in 1H Due to Planned Turnaround Activity a North Amer Plants >NTR.T

6 ago 2025, 22:03 UTC

Ganancias

Nutrien: Phosphate Sales Volume Guidance of 2.35MMT to 2.55MMT Assumes Improved Operating Rates, Sales Volumes in 2H Compared to Prior Yr With Completion of Planned Turnarounds in 1H >NTR.T

6 ago 2025, 22:03 UTC

Ganancias

Nutrien: Potash Sales Volume Guidance Was Increased to 13.9MMT to 14.5MMT Due to Expectations for Higher Global Demand in 2025 >NTR.T

6 ago 2025, 22:03 UTC

Ganancias

Nutrien 2Q EPS $2.50 >NTR.T

6 ago 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

A Family Feud Leaves the Future of This Kefir -2-

6 ago 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

A Family Feud Leaves the Future of This Kefir King in Doubt. Danone May Take Over. -- Barrons.com

6 ago 2025, 22:00 UTC

Charlas de Mercado
Ganancias

Airbnb 2Q Results Overshadowed by EBITDA Outlook -- Market Talk

6 ago 2025, 21:53 UTC

Adquisiciones, fusiones, absorciones

Parataxis Holdings: Combines Bitcoin Exposure, Proprietary Growth Opportunities, Accretive Yield Generation >SBXD

6 ago 2025, 21:53 UTC

Adquisiciones, fusiones, absorciones

Parataxis Holdings: Once Proposed Transaction Is Closed, Combined Co Will Be Named Parataxis Holdings Inc. and Seek to Trade on NYSE Under the Symbol 'PRTX' >SBXD

Comparación entre iguales

Cambio de precio

MannKind Corp Esperado

Precio Objetivo

By TipRanks

120.55% repunte

Estimación a 12 meses

Media 8.8 USD  120.55%

Máximo 11 USD

Mínimo 7 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MannKind Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.079 / 4.323Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

348 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.